This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $610,890 to Mayo Clinic to conduct research on improving immunotherapy response in intrahepatic cholangiocarcinoma (ICCA), a form of liver cancer.
The research aims to assess the clinical efficacy of a novel combination therapy involving external beam radiotherapy, intratumoral dendritic cell injections, and dual PD-L1/TIGIT blockade. This approach seeks to enhance the systemic expansion of tumor-reactive T cells and improve progression-free survival for patients with unresectable ICCA. The project will also use advanced techniques like single-cell RNA sequencing and T cell receptor sequencing to study the effects of this combination therapy on the tumor-reactive T cell repertoire. This research is expected to run from Sep 1, 2024 through Aug 31, 2029.
Generated 2/25/25, 2:59 AM